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Background: Despite evidence of an association between variants at the apolipoprotein L1 gene (APOL1) locus and
a spectrum of related kidney diseases, underlying biological mechanisms remain unknown. An earlier preliminary study
published by our group showed that an APOL1 variant (rs73885319) modified the association between high-density
lipoprotein cholesterol (HDLC) and estimated glomerular filtration rate (eGFR) in African Americans. To further understand
this relationship, we evaluated the interaction in two additional large cohorts of African Americans for a total of 3,592
unrelated individuals from the Howard University Family Study (HUFS), the Natural History of APOL1-Associated
Nephropathy Study (NHAAN), and the Atherosclerosis Risk in Communities Study (ARIC). The association between
HDLC and eGFR was determined using linear mixed models, and the interaction between rs73885319 genotype
and HDLC was evaluated using a multiplicative term.
Results: Among individuals homozygous for the risk genotype, a strong inverse HDLC-eGFR association was observed,
with a positive association in others (p for the interaction of the rs73885319 × HDLC =0.0001). The interaction was
similar in HUFS and NHAAN, and attenuated in ARIC. Given that ARIC participants were older, we investigated an
age effect; age was a significant modifier of the observed interaction. When older individuals were excluded, the
interaction in ARIC was similar to that in the other studies.
Conclusions: Based on these findings, it is clear that the relationship between HDLC and eGFR is strongly influenced
by the APOL1 rs73885319 kidney risk genotype. Moreover, the degree to which this variant modifies the association
may depend on the age of the individual. More detailed physiological studies are warranted to understand how
rs73885319 may affect the relationship between HDLC and eGFR in individuals with and without disease and across
the lifespan.
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The apolipoprotein L1 gene (APOL1) has been the focus
of considerable interest in recent years because of the dis-
covery of two coding genetic variants (G1 and G2) that
dramatically increase recessive risk of kidney diseases
among African Americans (AAs) [1–3]. Interestingly,
these variants are specific to African ancestry populations,
in which they are common. It is thought that these* Correspondence: rotimic@mail.nih.gov
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tection from African sleeping sickness, although it has
been suggested that selection for the G1 allele may reflect
a broader protective effect against pathogens [4]. While
the association between APOL1 variants and kidney dis-
ease has been confirmed for nephropathies of differing eti-
ologies, including focal segmental glomerulosclerosis
[1, 5], HIV-associated nephropathy [5], hypertension-
attributed end-stage kidney disease (ESKD) [1], severe
lupus nephritis [6], and chronic kidney disease (CKD) pro-
gression [7], the biological mechanism by which APOL1
variants influence renal function has not been elucidated.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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significant impact as it may suggest treatment options for
those with (or without) these risk variants.
High density lipoprotein cholesterol (HDLC) has been
positively associated with kidney function and inversely
with CKD risk [8–11] (although there are reports of an
opposite association [12–14]). The atheroprotective prop-
erties of the HDL particle may also protect glomerular
cells from damage and subsequent kidney dysfunction
[15–18]. In a preliminary analysis, our group has shown
that the association between HDLC and estimated glom-
erular filtration rate (eGFR), differed depending on the
genotype at rs73885319 which, along with a SNP in near-
perfect LD (rs60910145), defines the APOL1 G1 haplotype
[14]. Specifically, among individuals with the GG genotype
for rs73885319 (a kidney disease risk genotype), higher
HDLC was associated with lower eGFR, while there was
no association among those without this genotype. The
initial observation was made in the Howard University
Family Study (HUFS), a study of AAs designed to be
representative of the general AA population living in
Washington, DC. To further understand this relationship,
we evaluated the APOL1 ×HDLC interaction in AA from
two additional studies: the Natural History of APOL1-
Associated Nephropathy study (NHAAN) [19] and the
Atherosclerosis Risk in Communities study (ARIC) [20].
Methods
Participants and design
This analysis included AA individuals from the Howard
University Family Study (HUFS), the Natural History of
APOL1-Associated Nephropathy Study (NHAAN), and
the Atherosclerosis Risk in Communities Study (ARIC).
Briefly, HUFS is a study of AA that was designed to be
representative of the general population of AA living in
Washington, DC [21]. NHAAN is a study of AA first-
degree relatives of patients with non-diabetic ESKD [19].
ARIC was designed as a multi-ethnic study of atheroscler-
osis and recruited individuals aged 45–64 years in Forsyth
County, NC; Jackson, MS; the suburbs of Minneapolis,
MN; and Washington County, MD [20]. This analysis only
includes AAs from this study. ARIC data was accessed
through the Database of Genotypes and Phenotypes
(dbGaP) [22] (phs000280.v2.p1), specifically the GENEVA
substudy (phs000090.v2.p1), through an approved request
for controlled-access data. Included studies were ap-
proved by the Institutional Review Boards of Howard
University (HUFS), Wake Forest School of Medicine
(NHAAN), and, for ARIC, The University of North
Carolina at Chapel Hill, Johns Hopkins University, Uni-
versity of Mississippi Medical Center, Wake Forest Uni-
versity, University of Minnesota, Brigham and Women's
Hospital, and Baylor College of Medicine. Individuals with
T2D or CKD (eGFR < 60 ml/min/1.73 m2) were excludedfrom analysis given dyslipidemia associated with these
conditions.
Measurements
In all studies, HDLC was determined using standard
enzymatic procedures (in ARIC, dbGAP variable
phv00022850.v1.p1 was selected). Serum creatinine levels
were determined using a buffered kinetic Jaffé reaction
without deproteinization on a COBAS Integra 400 Plus
Analyzer (Roche Diagnostics, Indianapolis, IN) for HUFS.
In NHAAN, serum creatinine was measured using creati-
nase enzymatic spectrophotometry (LabCorp, Burlington,
NC; www.labcorp.com). For ARIC, serum creatinine levels
(phv00080483.v1.p1) were determined using the modified
kinetic Jaffé method [23] (DART Creatinine Reagent,
Coulter Diagnostics, Hialeah, FL). For all studies, eGFR
was calculated according to the race- and gender-specific
Chronic Kidney Disease Collaboration equations [24].
Genotyping
Genotyping at the APOL1 locus has been previously de-
scribed for both HUFS [14] and NHAAN [19]. For ARIC,
imputed genotype data for rs73885319 was accessed
(phg000248.v1), as well as genome-wide genotype data
(phg000035.v1.p1) for the calculation of African ancestry
proportion. The “best guess” genotypes based on the imput-
ation were used in the analysis. In HUFS, population
structure was assessed by principal component analysis
using EIGENSOFT [25], with the first PC, which repre-
sents African ancestry proportion, retained as previously de-
scribed [26]. African ancestry proportion was calculated using
ancestry informative markers in NHAAN. In ARIC, African
ancestry proportion was estimated using ADMIXTURE
[27] with K = 2 and random markers. HapMap3 YRI and
CEU samples were added to the ARIC samples to improve
the estimations.
Statistical analyses
HDLC was log-transformed in all analyses. As in the
previous analysis, rs73885319 was coded recessively:
those with the GG (kidney risk) genotype were com-
pared with individuals with the AG or AA genotypes.
The interaction between HDLC and rs73885319 was
evaluated in a linear regression model with a multiplica-
tive interaction term (HDLC × rs73885319, coded reces-
sively). In each model evaluating the interaction term,
terms for the main effect of HDLC and rs73885319 were
included. The presented pinteraction is the p-value for the
HDLC × rs73885319 term. The multiplicative interaction
term was calculated using mean-centered variables to
avoid collinearity. All models were adjusted for age, gen-
der, BMI, genome-wide proportion African ancestry, and
study along with the random effect of family (HUFS and
NHAAN both included family members). All analyses
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Figures were produced using data from a Least Squares
Means statement within the models (PROC MIXED;
LSMEANS), such that the models predicted eGFR given a
particular value of HDLC (evaluated at 30, 40, and 50 mg/
dl) and genotype (GG or AG/AA) with all other terms set to
their mean values. The points obtained from these condi-
tions were then plotted using R (http://www.r-project.org/).
While all models used log-transformed HDLC as a pre-
dictor, to produce a more easily interpretable figure, the
log of clinically meaningful HDLC values were input into
the LS Means statement and figure axes describe the rela-
tionship in mg/dl.
In previous analysis, an interaction between HDLC and
the G2 variant (rs71785313, a 6 bp deletion) on eGFR was
not observed; however, as most studies of APOL1 evaluate
the combined genotype of G1 (captured by rs73885319)
and G2 as the total number of variant alleles at this locus,
we also investigated the combined genotype and G2 separ-
ately, as follows. First, we modeled the interaction term as
described above, but with the APOL1 risk genotype defined
as those with two copies of variant alleles for either G1 or
G2 (i.e. homozygous for rs73885319 G or rs71785313 Del
or compound heterozygotes; there were no individuals
homozygous for the risk genotypes for both variants). For
comparison, we also modeled the interaction term
rs71785313 (coded recessively) × HDLC. As the G2 allele
was not available in ARIC, these models only included
HUFS and NHAAN participants.
Results
Included participants are described in Table 1. The fre-
quency of the GG genotype in HUFS was similar to what
was observed among AAs in the Exome Sequencing Pro-
jects (5.1 %; http://evs.gs.washington.edu/EVS/). The fre-
quency in NHAAN was more than twice that, consistent
with ascertainment of first-degree relatives of patients




Age (yrs) 42.3 ± 12.8 41.7 ± 13.1
BMI (kg/m2) 28.7 ± 7.6 31.4 ± 8.9
African Ancestry (%) 79.9 ± 11.2 79.0 ± 11.6
rs73885319 GG (%) 21 (4.3 %) 31 (4.1 %)
HDLC (mg/dl) 50.5 ± 14.9 54.7 ± 14.9
rs71785313 −/− (%) 10 (2.1 %) 18 (2.4 %)
2 APOL1 risk alleles (%)1 60 (12.5 %) 89 (12.1 %)
eGFR (ml/min/1.73 m2) 106.8 ± 18.8 107.7 ± 20.9
1Individuals with either rs73885319 GG or rs71785313 −/− or heterozygous for both
rs73885319 GG and rs71785313 −/−)factor. In ARIC, the GG frequency was lower than ex-
pected. Although the imputation score for this variant
was good (IMPUTE2 info score of 0.862), this distribution
may reflect the fact that rs73885319 was imputed in ARIC
(but genotyped in both HUFS and NHAAN). The distri-
bution of eGFR was consistent with an age effect, with
higher values observed in the studies with younger partic-
ipants. As expected given national statistics for AAs,
mean BMI for each study indicates a high degree of over-
weight and obesity, with substantially higher mean BMI
observed among women.
The association between HDLC and eGFR varied
based on genotype (p-value for HDLC × rs73885319
term [pinteraction] = 0.0001; Fig. 1a, Table 2). Among the
147 individuals with the GG genotype, a steep inverse
association between HDLC and eGFR was observed
(β -0.27 per 1 mg/dl increase in HDLC, p = 0.04 in a
stratified analysis). In contrast, among the 3445 individ-
uals with the AA or AG genotype, a positive association
was observed (β 0.05, p = 0.02). Notably, among those
with rs73885319 AA/AG, the observed HDLC-eGFR as-
sociation was similar to what we previously observed
among non-African ancestry individuals [14]. When each
study was considered separately (Fig. 1b-d), similar inter-
actions were observed in HUFS (pinteraction = 0.005; Fig. 1b)
and NHAAN (pinteraction = 0.006; Fig. 1c). The association
in ARIC, however, was quite different (pinteraction = 0.6;
Fig. 1d), with the slope of the association greatly attenu-
ated among GG individuals compared to what was ob-
served in HUFS and NHAAN. Given that participants in
ARIC were older than in HUFS and NHAAN, we hypothe-
sized that the difference in the interaction might be a func-
tion of age. We tested this hypothesis in the full sample
with an interaction term for HDLC× rs73885319 × age,
with age represented as a binary variable contrasting
those ≥55 years with those <55 years. The 3-way inter-
action term for HDLC× rs73885319 × age was statistically
significant (pinteraction = 0.02). When individuals ≥55 yearsNHAAN ARIC
Men Women Men Women
220 347 690 1086
46.4 ± 13.7 44.9 ± 13.1 53.1 ± 5.9 52.3 ± 5.5
29.3 ± 7.2 33.2 ± 9.0 27.3 ± 4.7 30.1 ± 6.3
79.5 ± 11.1 80.4 ± 9.8 83.0 ± 11.0 83.0 ± 10.9
25 (11.4 %) 34 (9.8 %) 9 (1.3 %) 27 (2.5 %)
48.1 ± 15.3 53.1 ± 16.8 51.6 ± 17.4 58.7 ± 17.1
6 (2.7 %) 11 (3.2 %) – –
46 (20.9 %) 89 (25.7 %) – –
98.6 ± 20.9 100.9 ± 21.4 78.2 ± 12.0 78.0 ± 11.9
rs73885319 and rs71785313 (no individuals were homozygous for both
Fig. 1 Association between eGFR and HDLC by rs73885319 genotype in African Americans. Plots from a model of eGFR as predicted by rs73885319 ×HDLC,
adjusted for rs73885319, HDLC, age, BMI, sex, genome-wide proportion African ancestry, study (for plot A), and the random effect of family. a. All
African Americans; b. Howard University Family Study (HUFS); c. Natural History of APOL1-Associated Nephropathy study (NHAAN); d. Atherosclerosis
Risk in Communities study (ARIC)
Table 2 Evaluation of the interaction between rs73885319 and HDLC on eGFR among African Americans by study
rs73885319 logHDL rs73885319 × logHDL
β (SE) P-value β (SE) P-value β (SE) P-value
HUFS, NHAAN, and ARIC combined −1.32 (1.26) 0.30 4.69 (2.08) 0.02 −37.42 (9.74) 0.0001
HUFS 0.51 (2.45) 0.83 −0.12 (4.30) 0.98 −52.12 (18.55) 0.005
NHAAN −3.73 (2.34) 0.11 7.09 (6.11) 0.25 −50.35 (18.18) 0.006
ARIC −1.84 (2.06) 0.37 8.03 (2.24) 0.0003 −10.30 (17.03) 0.55
ARIC (≤55 years) −2.17 (2.59) 0.40 7.69 (2.88) 0.008 −29.78 (21.78) 0.17
HUFS, NHAAN, and ARIC combined (≤55 years) −1.24 (1.50) 0.41 5.31 (2.54) 0.04 −49.47 (11.44) 0.00002
Results are from a model of eGFR as predicted by rs73885319 × HDLC, adjusted for rs73885319, HDLC, age, BMI, sex, genome-wide proportion of African ancestry,
study (where combined), and the random effect of family
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to what was observed for HUFS and NHAAN (Fig. 2a);
however, there were only 24 GG individuals remaining,
and the interaction did not reach statistical significance
(pinteraction = 0.17). When HUFS, NHAAN, and ARIC wereFig. 2 Association between eGFR and HDLC by rs73885319 genotype
in African Americans < 55 years. Plots from a model of eGFR as predicted
by rs73885319 × HDLC, adjusted for rs73885319, HDLC, age, BMI, sex,
genome-wide proportion African ancestry, study (for plot B), and the
random effect of family. a. Atherosclerosis Risk in Communities study
(ARIC); b. All African Americansjointly analyzed excluding older individuals, the inter-
action was similar to that in the full set, but more statisti-
cally significant (pinteraction = 0.00002; Table 2; Fig. 2b).
APOL1 effects are generally described in terms of
“number of risk variants,” a collapsing of variation at the
G1 and G2 haplotypes. rs73885319, evaluated in this
study, effectively captures the G1 haplotype, as the other
G1 SNP, rs60910145, is in near-perfect LD with
rs73885319 (r2 = 1.0 among AFR [28]). We also consid-
ered G2 separately and with G1 (number of APOL1 risk
variants) in this analysis. These analyses were limited to
the HUFS and NHAAN datasets (the G2 variant was not
available in ARIC). No interaction was observed with
the G2 haplotype (pinteraction = 0.9; Table 3). When num-
ber of APOL1 risk variants were evaluated, the inter-
action was weaker than was observed with rs73885319
on its own (presented here with only HUFS and
NHAAN for comparison). The results from this coding
are consistent with the dilution of the rs73885319 inter-
action by including G2.
To be sure that the recessive coding of rs73885319 was
appropriate, we also evaluated the addition of an interaction
term for heterozygotes (rs73885319 AG×HDLC) to the
model (Additional file 1). The regression coefficient (β) for
the rs73885319 AG×HDLC term was neither intermediate
(suggesting an additive effect) nor similar to that of the
rs73885319 GG×HDLC term (suggesting a dominant ef-
fect). It was not statistically significant (pinteraction = 0.5)
and the inclusion of this term did not affect the size or
significance of the rs73885319 GG ×HDLC term; thus,
we feel confident that the interaction pertains only to in-
dividuals with the GG genotype, and the recessive coding
best fits our data.
To evaluate the robustness of the rs73885319 ×HDLC
findings to analytic strategy, we conducted sensitivity ana-
lyses. First, since dyslipidemia frequently occurs jointly
with T2D and CKD, individuals with these conditions
were excluded to limit their influence on HDLC. When
these individuals were included, the interaction remained
statistically significant, though attenuated (pinteraction =
0.01; Additional file 2). Second, the choice of an appropri-
ate kidney function measure can be debated. While we de-
scribe results using eGFR as estimated by the Chronic
Kidney Disease Collaboration equations [24], similar inter-
actions were observed when using eGFR calculated using
the Modification of Diet in Renal Disease study equations
[29] or with serum creatinine concentration (data not
shown). Finally, there was no difference in rs73885319 ×
HDLC interaction by gender (p value for the interaction
of gender × rs73885319 ×HDLC = 0.56).
Discussion
In 3,592 African American participants from three independ-
ent studies (HUFS, NHAAN, and ARIC), we demonstrated
Table 3 Evaluation of the interaction between APOL1 risk variants and HDLC on eGFR among African Americans1
APOL1 variant logHDL APOL1 variant × logHDL
APOL1 Variant tested β (SE) P-value β (SE) P-value β (SE) P-value
rs73885319 (only) −1.48 (1.69) 0.38 1.85 (3.53) 0.60 −44.3 (12.8) 0.0006
rs71785313 (only) 0.05 (2.58) 0.98 −0.70 (3.47) 0.84 −2.8 (22.5) 0.90
APOL1 risk genotype (both)2 −1.47 (1.12) 0.19 3.02 (3.72) 0.42 −24.1 (8.7) 0.005
Results from a model of eGFR as predicted by APOL1 variant × HDLC, adjusted for variant, HDLC, age, BMI, sex, genome-wide proportion African ancestry, study,
and the random effect of family. 1Data are presented for HUFS and NHAAN only, as rs71785313 was not available in ARIC; 2Individuals with either rs73885319 GG
or rs71785313 −/− or heterozygous for both rs73885319 and rs71785313 (no individuals were homozygous for both rs73885319 GG and rs71785313 −/−) compared to
individuals who were heterozygous for either rs73855319 or rs71785313 or homozygous for the reference allele for both
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influenced by the kidney risk genotype (GG) at rs73885319
in the APOL1 gene. Among the 147 individuals with the GG
genotype, a steep inverse association between HDLC and
eGFR was observed. In contrast, among the 3445 individuals
with the AA or AG genotype, HDLC was positively associ-
ated with eGFR. The mechanism underlying this APOL1 ×
HDLC interaction is not clear. A potential explanation
that has been recently suggested [30] is that rs73885319
directly or indirectly leads to qualitative changes in the
HDL particle that render it dysfunctional in terms of its
protective properties. While HDL is generally character-
ized as an anti-inflammatory, antioxidant particle, under
certain conditions, including coronary artery disease, dia-
betes mellitus (types 1 and 2), metabolic syndrome, and
kidney disease (reviewed in [31]), it loses some of its bene-
ficial properties, potentially becoming pro-inflammatory
and pro-oxidant. The generally protective function of the
HDL particle is attributed to its role in reverse cholesterol
transport as well as to the lipid and protein components
of which it is composed. HDL is a heterogeneous macro-
molecular complex that contains more than 80 proteins
and peptides, more than 200 lipid species, and several
microRNAs [31]. The distribution of these components is
responsive to a variety of biological changes, such as in-
flammation and oxidative stress [31]. During the acute
phase response, for instance, HDL was shown to have re-
duced apoA-I levels and paraoxonase activity and in-
creased ceruloplasmin (an acute phase reactant) [32].
HDL proteomic remodeling was observed in patients with
coronary artery disease; compared to the HDL from
healthy individuals, the HDL from patients had higher
apoC-III and lower clustering, and stimulated endothelial
pro-apoptotic pathways [33]. In the Nurses’ Health Study
and the Health Professionals’ Follow-up Study, HDL
proteomic differences, specifically apoC-III presence or
absence, determined the direction of association between
HDL and cardiovascular disease risk, with the HDL/apoC-
III complex associated with increased risk [34]. With such
findings, it is becoming increasingly appreciated that the
measurement of HDLC, the cholesterol content of the
HDL particle, is simply a proxy for particle number, and
does not represent the particle’s proteome and lipidome,which may be more important in terms of disease risk. It
is expected that studies evaluating the content of HDL
particles in a more refined way would be informative for
the interaction observed in this study.
Differences in the rs73885319 ×HDLC interaction were
seen by age. An older age could represent increased oxida-
tive stress and inflammation, among other factors. While
we were not able to further evaluate the underlying mech-
anism of this difference in these studies, one potential ex-
planation is that aging influences the composition and/or
function of the HDL particle in ways that are relevant for
this interaction. Aging has been previously associated with
decreased HDL-mediated reverse cholesterol transport
[35], HDL antioxidant activity [36], and PON1 activity, ir-
respective of changes in PON1 or HDLC concentration
[37]. Thus, in the context of HDL with decreased protect-
ive capacity as observed with aging, APOL1-influenced
changes to HDL quality may be more difficult to detect.
It would be reasonable to suspect that the observed
modification of the association between HDLC and
eGFR by rs73885319 may be relevant for cardiovascular
disease risk, as HDLC has generally been associated with
improved cardiovascular health and APOL1 kidney dis-
ease risk variants have been associated with increased
CVD risk [38] (although the evidence is not consistent
across studies [7, 39, 40]). It may be hypothesized that if
rs73885319 contributes directly or indirectly to qualita-
tive changes in the HDL particle that alter the relation-
ship between HDL and kidney function, those changes
might also affect the association between HDLC and
CVD-related outcomes in unexpected ways. Given the
uncertainty regarding the underlying biological mecha-
nisms that this statistical interaction captures, it is diffi-
cult to speculate what may be observed.
Conclusions
The present study confirms and extends the earlier ob-
servation that the association between HDLC and eGFR
differs depending on rs73885319 genotype at the APOL1
kidney disease locus. Among individuals with the
rs73885319 GG (kidney disease risk) genotype, higher
HDLC was associated with lower eGFR, while a positive
association was observed among those without this
Bentley et al. BMC Genomics  (2015) 16:421 Page 7 of 8genotype. In this analysis, a modulatory effect of age on
the rs73885319 × HDLC interaction was observed, such
that the interaction was attenuated among older individ-
uals. Functional studies are needed to reveal the patho-
physiologic mechanisms underlying this interaction.
Availability of supporting data
All of the ARIC data used in this analysis was from the
GENEVA substudy and can be accessed through dbGaP
(http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000090.v2.p1). Participants in HUFS and
NHAAN were not consented for wide data release (such
as in a publicly-available database), but data can be
made available for collaborative research. Additionally,
summary-level statistics on these data will be provided
upon request.
Additional files
Additional file 1: Effect of variant coding on APOL1 rs73885319 ×
HDLC interaction. Results from a model of eGFR in HUFS, NHAAN, and
ARIC individuals including terms for rs73885319 (coded as # of variant
alleles), HDLC, rs73885319 AG × HDLC, rs73885319 GG × HDLC, age, BMI,
sex, study, and genome-wide proportion African ancestry and a random
term for family.
Additional file 2: Association between eGFR and HDLC by rs73885319
genotype, T2D and CKD included. Results from a model of eGFR as
predicted by rs73885319 × HDLC, adjusted for rs73885319, HDLC, age,
BMI, sex, genome-wide proportion African ancestry, study, and the
random effect of family. In contrast to main models, no exclusion has
been made for type 2 diabetes (T2D) or chronic kidney disease (CKD).
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